Venetoclax is an oral targeted medicine that triggers cancer cells to self-destruct by blocking a protein that normally helps them survive. It belongs to a class of medicines called BCL-2 inhibitors, used for chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), and certain cases of acute myeloid leukaemia (AML). It is a prescription-only medicine that requires a carefully managed dose ramp-up due to a specific safety risk.

Therapeutic Class: Anti-cancer (oncology) targeted therapy for blood cancers.

Pharmacological Class: B-cell lymphoma-2 (BCL-2) inhibitor.

Drug Family: Small-molecule apoptosis-inducing agents.

ATC Classification: L01XX52 (Venetoclax).

Approved: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in adults, as monotherapy or in combination regimens; and newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude intensive induction chemotherapy, in combination with azacitidine, decitabine, or low-dose cytarabine.

Commonly used for: Patients with CLL/SLL across first-line and relapsed/refractory settings, and older or medically unfit AML patients unable to tolerate intensive chemotherapy.

Off-label use (only under medical guidance): Being studied in other blood cancers and solid tumours in clinical trials; not routine outside its approved indications.

• Oral tablets: 10 mg, 50 mg, and 100 mg (with a starting-pack option providing the ramp-up doses needed for the first weeks of treatment).

Cancer cells, particularly in CLL and AML, often rely heavily on a protein called BCL-2 to avoid a natural process of cell self-destruction called apoptosis. Venetoclax blocks BCL-2, removing this survival signal and allowing the cancer cells to undergo apoptosis, which helps reduce the number of leukaemia cells in the body.

• Standard dose (CLL/SLL, after ramp-up): Dosing begins with a 5-week ramp-up schedule (starting at 20 mg once daily and gradually increasing weekly) to the target dose of 400 mg orally once daily, designed to gradually reduce tumour burden and lower the risk of tumour lysis syndrome (TLS).

• Condition-wise dose (AML): A shorter ramp-up (typically 3 days: 100 mg, 200 mg, 400 mg) is used, followed by 400 mg once daily (in combination with azacitidine or decitabine) or 600 mg once daily (in combination with low-dose cytarabine), for each 28-day cycle.

• Route: Oral, once daily, taken with food at approximately the same time each day; tablets should be swallowed whole.

• Missed dose: If a dose is missed by less than 8 hours, take it as soon as possible on the same day; if missed by more than 8 hours, skip it and resume the normal schedule the next day.

• Overdose: Can significantly increase the risk of tumour lysis syndrome and other known side effects; requires urgent medical attention.

Common: Low blood counts (neutropenia, anaemia, thrombocytopenia), diarrhoea, nausea, fatigue, and upper respiratory infections.

Serious: Tumour lysis syndrome (a potentially life-threatening reaction, especially during the ramp-up phase), severe neutropenia with infection risk, and, rarely, serious infections.

Emergency symptoms: Signs of tumour lysis syndrome (nausea, vomiting, confusion, shortness of breath, irregular heartbeat, dark or reduced urine output — particularly in the first days of treatment or after a dose increase), or signs of serious infection (fever, chills).

Recovery advice: Adequate hydration and, where prescribed, uric-acid-lowering medicines before the first dose and during dose increases are central to reducing tumour lysis syndrome risk; blood counts are checked frequently, especially early in treatment.

• Pregnancy: Not recommended; may cause fetal harm.

• Breastfeeding: Not recommended during treatment.

• Liver disease: Used with caution; dose adjustment may be needed in significant impairment.

• Kidney disease: Reduced kidney function (creatinine clearance under 80 mL/min) further increases TLS risk, requiring more intensive monitoring/prophylaxis.

• Elderly: Commonly used in this age group, particularly for AML in patients 75 and older or those unfit for intensive chemotherapy.

• Children: Not established for use in children.

• Strong CYP3A inhibitors: contraindicated during initiation and the ramp-up phase in CLL/SLL due to significantly increased TLS risk; requires dose reduction if combined use is needed during AML ramp-up or steady dosing.

• Strong CYP3A inducers: can significantly reduce venetoclax effectiveness; avoided.

• P-glycoprotein (P-gp) inhibitors: increase venetoclax exposure, requiring dose reduction.

• Warfarin and other narrow-therapeutic-index P-gp substrate drugs: venetoclax may increase their levels, requiring closer monitoring.

• Blood chemistries (potassium, uric acid, phosphorus, calcium, creatinine) closely monitored, especially around the first dose and each dose increase during ramp-up.

• Complete blood counts regularly throughout treatment.

• Kidney function tests, given the TLS-related kidney risk.

• Monitoring for signs of infection given the significant neutropenia risk.

Ibrutinib, Acalabrutinib (BTK inhibitors, different mechanism, used in overlapping CLL settings); other AML induction approaches for patients able to tolerate more intensive treatment.

Used as monotherapy or combined with obinutuzumab/rituximab for CLL/SLL; combined with azacitidine, decitabine, or low-dose cytarabine for AML in patients unsuitable for intensive chemotherapy.

• Chronic Lymphocytic Leukaemia (CLL) Medicines

• Acute Myeloid Leukaemia (AML) Medicines

• BCL-2 Inhibitors

1. Lymph Cancer Symptoms, Types and Warning Signs

2. Know About Multiple Myeloma Symptoms And Prognosis

• https://www.rxabbvie.com/pdf/venclexta.pdf

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10931175/

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your oncologist to know if this treatment is appropriate for your condition.